Genetic risk and likelihood of prostate cancer detection on first biopsy by ancestry.
By: Kyung Min Lee, Tyler Nelson, Alex Bryant, Craig Teerlink, Roman Gulati, Meghana Pagadala, Catherine Tcheandjieu, Kathryn M Pridgen, Scott L DuVall, Kosj Yamoah, Jason L Vassy, Tyler M Seibert, Richard Hauger, Brent S Rose, Julie A Lynch

VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, USA.
2023-8-10; doi: 10.1093/jnci/djae002
Abstract

Despite differences in prostate cancer risk across ancestry groups, relative performance of prostate cancer genetic risks scores (GRS) for positive biopsy prediction in different ancestry groups is unknown. This cross-sectional retrospective analysis examines the association between a polygenic hazard score (PHS290) and risk of prostate cancer diagnosis upon first biopsy in male Veterans using two-sided tests. Our analysis included 36,717 Veterans (10,297 of African ancestry). Unadjusted rates of positive first prostate biopsy increased with higher genetic risk (low risk: 34%, high risk: 58%; p < .001). Among men of African ancestry, higher genetic risk was associated with increased prostate cancer detection on first biopsy (OR 2.18, 95% CI 1.93-2.47), but the effect was stronger among men of European descent (OR 3.89, 95% CI 3.62-4.18). These findings suggest that incorporating genetic risk into prediction models could better personalize biopsy decisions, although further study is needed to achieve equitable genetic risk stratification among ancestry groups.



Published by Oxford University Press 2024.

PMID:38212986






Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements